Ophthalmology Month in Review: July 2025

Although July was a relatively quiet month for ophthalmology on the US Food and Drug Administration’s front, it did see substantial growth in research across the board. Geographic atrophy, diabetic macular edema, neovascular age-related macular degeneration, and more diseases all saw significant steps forward in treatment and diagnosis. New medications and therapies have advanced significantly through successful clinical trials, and while few are currently at the approval stage, each one shows substantial promise.